Form 4: Entrada Therapeutics Director Sells Shares
Insider Transaction (Form 4)
Kush Parmar, a Director of Entrada Therapeutics, Inc., sold 155,255 shares of common stock on August 6, 2026.
Summary
- Open-market sale: disposed of 10,494 Common Stock at $7.00 ($73,458) on August 6, 2026; holds 2,836,098 after (Indirect).
- Open-market sale: disposed of 52,317 Common Stock at $6.85 ($358,371) on August 7, 2026; holds 2,783,781 after (Indirect).
- Open-market sale: disposed of 92,444 Common Stock at $7.00 ($647,108) on August 10, 2026; holds 2,691,337 after (Indirect).
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $1,078,937 of stock on the open market.
Insider Transactions
Kush Parmar — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-06 | Open-market sale | Common Stock | 10,494 | $7 | $73.5K | 2,836,098 |
| 2026-08-07 | Open-market sale | Common Stock | 52,317 | $7 | $358.4K | 2,783,781 |
| 2026-08-10 | Open-market sale | Common Stock | 92,444 | $7 | $647.1K | 2,691,337 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-06 | Open-market sale (10,494 shares) |
| 2026-08-07 | Open-market sale (52,317 shares) |
| 2026-08-10 | Open-market sale (92,444 shares) |
Keywords
insider transaction, Form 4, TRDA, Entrada Therapeutics, Inc., bearish, Kush Parmar
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.